SHC1 and breast carcinoma: To focus on antibodies with this property, we developed a 96-well plate-based affinity capture screen that enabled the screening of hundreds of clones simultaneously for their ability to bind endogenous full-length SHC1 from a breast cancer epithelial cell lysate.